Gilead's Biktarvy Medicare Price Is Now Set, Effective January 1, 2028

The drugmaker's quarterly report replaces a hedged warning with a finished Medicare negotiation for its $4.06 billion-a-quarter HIV drug.

Share
Gilead's Biktarvy Medicare Price Is Now Set, Effective January 1, 2028

Gilead Sciences, which develops medicines for HIV, viral hepatitis, COVID-19 and cancer, said in its quarterly report filed Friday that Medicare has finished setting a price for Biktarvy, its biggest drug, that is "substantially lower than the price we currently charge in Medicare." The new price starts hitting Biktarvy revenue on January 1, 2028.

From forecast to finished price

Medicare's price negotiation for Biktarvy wrapped up in October 2026, with CMS fixing the Maximum Fair Price. The risk factors say the price also lowers 340B ceiling prices (the discount tier for safety-net providers) and raises Medicaid rebates.

The prior quarter's filing went only as far as saying Gilead anticipated the negotiated Medicare price would be substantially lower, and that it was still evaluating the impact. That forecast is now a completed pricing event.

Biktarvy brought in $4.06 billion of third-quarter product sales, up 10% from a year earlier, so the largest product now has a fixed Medicare cut on the calendar. Reuters reported the cut at 38%, a figure from its own coverage.

A second pricing rule

The risk factors also add a September 2026 final rule from CMS creating the GLOBE Model. Beginning in April 2027, it will tie certain Medicare Part B rebates to most-favored-nation prices. Gilead would be exempt from GLOBE while it takes part in the GENEROUS Model, CMS has said.

Earnings held up; deals piled on

Third-quarter revenue rose 7% to $8.3 billion, and net income was $2.4 billion, or $1.94 a share, against $3.1 billion, or $2.43, a year earlier. For the nine months, Gilead posted a net loss of $6.0 billion, driven by acquired research charges tied to its Arcellx, Tubulis and Ouro Medicines purchases and a $1.75 billion impairment on a Trodelvy lung-cancer asset.

Gilead also struck an October deal to buy PepStar's HCXT-2001 and the rest of its oral IL-23R program for $1.275 billion upfront. It expects to close in the fourth quarter of 2026 and to account for it as an asset acquisition. Cash stood at $6.4 billion at September 30, and the company declared a quarterly dividend of $0.82 a share.

The FDA's target decision date for Gilead's anito-cel multiple myeloma application is December 23, 2026, and the PepStar deal is expected to close in the fourth quarter.

Sources

More on Gilead Sciences

All Gilead Sciences (GILD) coverage →